31,752 Shares in Glaukos Co. (NYSE:GKOS) Bought by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. bought a new position in shares of Glaukos Co. (NYSE:GKOS - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 31,752 shares of the medical instruments supplier's stock, valued at approximately $4,761,000. Balyasny Asset Management L.P. owned approximately 0.06% of Glaukos at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. IFP Advisors Inc bought a new stake in shares of Glaukos in the 4th quarter valued at about $43,000. Asset Planning Inc bought a new stake in shares of Glaukos in the 4th quarter valued at about $90,000. Picton Mahoney Asset Management bought a new stake in shares of Glaukos in the 4th quarter valued at about $125,000. SBI Securities Co. Ltd. bought a new stake in shares of Glaukos in the 4th quarter valued at about $153,000. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Glaukos by 275.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after buying an additional 807 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on GKOS. Mizuho lowered their price target on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 16th. Truist Financial reissued a "buy" rating and set a $135.00 target price (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Wells Fargo & Company downgraded shares of Glaukos from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $160.00 to $86.00 in a research report on Thursday, May 1st. Morgan Stanley dropped their target price on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus dropped their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Glaukos has an average rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Stock Performance

NYSE GKOS traded up $2.91 on Friday, hitting $94.53. 191,980 shares of the company's stock traded hands, compared to its average volume of 683,495. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 1-year low of $77.10 and a 1-year high of $163.71. The firm's 50-day moving average price is $93.95 and its two-hundred day moving average price is $126.28. The firm has a market capitalization of $5.40 billion, a PE ratio of -32.95 and a beta of 0.83.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. During the same period in the previous year, the business posted ($0.70) EPS. The business's quarterly revenue was up 24.6% compared to the same quarter last year. As a group, analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Insider Activity at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. The trade was a 2.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 5.80% of the company's stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.